Study to Evaluate Tezepelumab in Adults & Adolescents with Severe Uncontrolled Asthma - NAVIGATOR

Study identifier:D5180C00007

ClinicalTrials.gov identifier:NCT03347279

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (NAVIGATOR)

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

1061

Study type

Interventional

Age

12 Years - 80 Years

Date

Study Start Date: 23 Nov 2017
Primary Completion Date: 08 Sept 2020
Study Completion Date: 12 Nov 2020

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2021 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Amgen

Inclusion and exclusion criteria